Navigation Links
Covance to Present at the Drug Information Association's 45th Annual Meeting
Date:6/16/2009

- Covance experts to present best practices for improving drug safety and reducing R&D time, cost -

PRINCETON, N.J., June 16 /PRNewswire-FirstCall/ -- Covance Inc. is pleased to announce the complete list of experts scheduled to present at the Drug Information Association's (DIA) 45th Annual Meeting from June 21-25, 2009 in San Diego, Calif.

The DIA Annual Meeting is the biopharmaceutical industry's largest, longest running, global, multidisciplinary event. This year's program offers learning opportunities for everyone and features the biggest names from industry, regulatory, and academia.

Building on the conference theme, "Better Medicines: Improving Safety with Every Step," Covance experts will present best practices for improving safety while reducing the time and cost of drug development, including:

June 22, 2009:

  • "Innovation at a CRO: A Strategic Management Platform to Enhance Overall Value of a Client's Portfolio"

10:30 a.m. | Speaker: Krish Ghosh, PhD, vice president, resource management

  • "Issues and Challenges Associated with the PSUR Process"

1:30 p.m. | Session Chair: Robert Bader, PharmD, senior director, product safety, periapproval services

  • "Improving Safety with Expanded Training Options for Physicians in Early Phases of Clinical Research"

1:30 p.m. | Speaker: Russ Dixon, MD, medical director, early clinical development

  • "EDC Front to Back: Streamline Processes End-to-End for True Operational Benefit"

3:30 p.m. | Speaker: Ross Rothmeier, senior director, EDC portfolio, clinical development services

June 23, 2009:

  • "Corrective Action and Preventive Action Program for Clinical Trial Programs"

8:00 a.m. | Session Chair: Bruce Wagman, MBA, RN, RAC, vice president, regulatory affairs and quality assurance, clinical development services

  • "Routine Monitoring Visits: Pragmatic Approaches to Reduce Prep Time by More Than 50%"

9:30 a.m. | Poster Presentation: Ann Flandermeyer, BSN, PhD, MSN, RN, project management and clinical operations

  • "Early Exposure to the Science of Safety Through Clinical Research in a CRO Setting for Future Medical Professionals"

9:30 a.m. | Poster Presentation: Jackie Miller-Giles, MT (ASCP), MS, global clinical pharmacology

  • "Nonclinical Support for First-in-Human Clinical Trials"

2:00 p.m. | Speaker: Paul Baldrick, PhD, head of department, pharmaceutical regulatory affairs

  • "Defining Quality in Clinical Trials (2nd Annual Update)"

2:00 p.m. | Session Chair: John Poland, PhD, senior director, regulatory policy, UK, clinical development services

  • "Changes in the WHO Review of Psychoactive Substances for International Control"

4:00 p.m. | Session Chair: Edgar Adams, ScD, MS, executive director, epidemiology, periapproval services

  • "Site Preferences for EDC - A Comparison of European and North American Perspectives"

4:00 p.m. | Session Chair: Eunice Franklin-Becker, MPH, senior project manager, registries and observational studies, periapproval services

  • "First-In-Human Trial Designs: How Much is Too Much?"

4:00 p.m. | Session Chair: Mary Westrick, PhD, global vice president and general manager, clinical pharmacology

June 24, 2009:

  • "Six Sigma: How to Leverage 'A Great Idea' in the Complex Reality of Clinical Trials"

8:30 a.m. | Session Chair: Tim G. Strauss, MA, executive director, business process improvement, clinical development services

  • "Outsourced Data Management: How to Align Performance Expectations"

10:30 a.m. | Session Chair: Mark Anderson, senior director, data management, clinical development services

  • "Site Activation: How to Get Beyond the Classic Pitfalls"

1:30 p.m. | Speaker: Heather Almonte, MBA, RAC, senior manager, site activation, clinical development services

  • "An Overview of Challenges and Strategies to Make Remote Investigator Training a Reality"

3:30 p.m. | Speaker: Christina Werremeyer, project manager, periapproval services

  • "Latin America: Leveraging Regional Strengths While Proactively Ensuring Quality"

3:30 p.m. | Session Chair: Katie Margules, PharmD, MSc, senior director, clinical development services, Latin America

June 25, 2009:

  • "Proactive Management of Project Financials: Understand Scope of Work, Cost to Complete, and Scope Change"

8:30 a.m. | Session Chair: Ann Flandermeyer, BSN, PhD, MSN, RN, senior director, project management and clinical operations, clinical development services

  • "Preserving Relationships in the Face of Divergent Project Expansions"

8:30 a.m. | Speaker: Mike Hill, project manager, periapproval services

  • "Preclinical Safety Evaluation of Novel Adjuvants and Vaccines"

10:30 a.m. | Session Chair: Peter Thomas, PhD, senior program manager, strategic partnering & integrated drug development

About Covance

Covance, with headquarters in Princeton, New Jersey, is one of the world's largest and most comprehensive drug development services companies with annual revenues greater than $1.5 billion, global operations in more than 25 countries, and more than 9,600 employees worldwide. Information on Covance's products and services, recent press releases, and SEC filings can be obtained through its website at www.covance.com.

About the Drug Information Association (DIA)

DIA serves more than 30,000 biopharmaceutical professionals from industry, academia, and regulatory agencies worldwide. Through its domestic and international meetings, training courses, workshops and webinars, DIA provides a neutral global forum for the exchange of information critical to the advancement of the drug discovery and lifecycle management processes. Headquartered in Horsham, PA, USA, and with offices in Basel, Switzerland, Tokyo, Japan, Mumbai, India, and Beijing, China, the Association is led by its volunteer-based Board of Directors and executive management team. For more information, visit www.diahome.org or call 215.442.6100.

Statements contained in this press release, which are not historical facts, are forward-looking statements pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All such forward-looking statements including the statements contained herein regarding anticipated trends in the Company's business are based largely on management's expectations and are subject to and qualified by risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. These risks and uncertainties include, without limitation, competitive factors, outsourcing trends in the pharmaceutical industry, levels of industry research and development spending, the Company's ability to continue to attract and retain qualified personnel, the fixed price nature of contracts or the loss of large contracts, and other factors described in the Company's filings with the Securities and Exchange Commission.


'/>"/>
SOURCE Covance Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Covance Elects John McCartney to Companys Board of Directors
2. Covance Reports First Quarter Revenue of $441M and EPS of $0.63; Updates Full Year Financial Targets
3. Covance Opens New Clinical Development Offices in Chile, Peru and Expands Argentina Office
4. Jina Ventures Advises Swiss Pharma Contract on Strategic Sale to Covance Inc
5. Covance Increases Early Clinical Footprint in Europe with Acquisition of Swiss-Based Early Clinical Development Site
6. Covance Purchases Equity Stake in Caprion Proteomics
7. Covance and Lilly Finalize 10-Year, $1.6 Billion Strategic R&D Collaboration
8. Covance Decides to Pursue Its Original Preclinical Strategy in China
9. Covance and WuXi PharmaTech to Form a Joint Venture to Provide World-Class Preclinical Services in China
10. Covance to Present at The R.W. Baird 2008 Growth Stock Conference
11. Covance to Present at Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... , Feb. 10, 2016  The Maryland House of ... has announced that University of Maryland School of Medicine ... and University of Maryland Medical System President and CEO ... "Speaker,s Medallion," the highest honor given to the public ... Dean Reece and Mr. Chrencik for ...
(Date:2/10/2016)... -- IsoRay, Inc. (NYSE MKT: ISR), a medical technology company ... for the treatment of prostate, brain, lung, head and ... for the second quarter and six months of fiscal ... --> --> Revenue was $1.19 ... ended December 31, 2015, a 12% increase compared to ...
(Date:2/10/2016)... (PRWEB) , ... February 10, 2016 , ... ... attend the International Society of Pharmaceutical Engineering (ISPE) Rocky Mountain Chapter 21st Annual ... is expecting to fill more than 100 tables for its annual event, which ...
(Date:2/10/2016)... (PRWEB) , ... February 10, 2016 , ... ... now available on Microsoft Azure. On Azure, Arvados provides capabilities for managing and ... clear demand for Microsoft Azure from major institutions collecting and analyzing genomic data,” ...
Breaking Biology Technology:
(Date:1/18/2016)... JOSE, Calif. , Jan. 18, 2016 /PRNewswire/ ... security software that simplifies the use and access ... technology and go-to-market partnership with American Cyber.  ... Cyber brings extensive experience leading transformational C4ISR and ... implementing and integrating the latest proven technology solutions," ...
(Date:1/13/2016)... DUBLIN , January 13, 2016 ... has announced the addition of the  ... - Estimation & Forecast (2015-2020)" ... http://www.researchandmarkets.com/research/7h6hnn/india_biometrics ) has announced the ... & Identification Market - Estimation & ...
(Date:1/8/2016)... Kingdom , Jan. 8, 2016   Bruin Biometrics, ... today announced the closing of a $9 million financing. The ... the financing will be used to accelerate the commercialization of ... early-stage pressure ulcers. United Kingdom ... Mark approval. The device,s introduction has been met with enthusiasm ...
Breaking Biology News(10 mins):